NanoViricides, Inc. is a global leader in the development of nanomedicine drugs against viruses. Our unique nanoviricide® platform technology defines a novel mechanism enabling first-in-class drugs against viruses. NanoViricides is one of the few biopharma companies with its own multi-kilogram-scale c-GMP capable manufacturing facility for the drug substance as well as drug product, in Shelton, CT. This facility is fully owned by the Company with no mortgage and is a major asset. This flexible, multi-product pilot plant can supply drug product for all of our programs through human clinical trials. Our cGMP manufacturing ability enables substantial time and cost savings in our drug development programs. Further, it is capable of production for initial marketing, enabling early revenues upon drug approval, of about $100MM~$500MM per year.